Debu Tripathy, MD, on HR+, HER2– Breast Cancer: Results From the MONALEESA-7 Trial

2017 San Antonio Breast Cancer Symposium

Debu Tripathy, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III study findings on first-line ribociclib vs placebo with goserelin and tamoxifen or a nonsteroidal aromatase inhibitor in premenopausal women with hormone receptor–positive, HER2-negative advanced breast cancer (Abstract GS2-05).



Related Videos

Breast Cancer

Melinda Telli, MD, on Triple-Negative Breast Cancer: New Clinical Approaches

Melinda Telli, MD, of the Stanford University School of Medicine, discusses the current status of treatment for advanced TNBC, and new therapeutic strategies now being used for bet...

Breast Cancer

Louis Fehrenbacher, MD, on Invasive Breast Cancer: Results From the NSABP B-47 Trial

Louis Fehrenbacher, MD, of Kaiser Permanente, discusses study findings comparing adjuvant chemotherapy with doxorubicin and cyclophosphamide followed by weekly paclitaxel—or doceta...

Breast Cancer

Lee S. Schwartzberg, MD, on HR+ Breast Cancer: Treatment Trial Results

Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase II study findings evaluating exemestane with or without enzalutamide in patients with hormone receptor–positive ...

Breast Cancer

Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, on HER2+ Metastatic Breast Cancer: Results From the PANACEA/KEYNOTE 014 Trial

Sherene Loi, MD, PhD, and Roberto Salgado, MD, PhD, both of the Peter MacCallum Cancer Centre, discuss study findings on pembrolizumab and trastuzumab in patients ...

Breast Cancer

Richard G. Gray, MSc, on Adjusting Adjuvant Chemotherapy Dosing: Results From an EBCTCG Analysis

Richard G. Gray, MSc, of the University of Oxford, discusses an Early Breast Cancer Trialists’ Collaborative Group meta-analysis of 21,000 women in 16 randomized trials, which show...

Advertisement

Advertisement



;
Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.